Introduction {#Sec1}
============

The possibility of a link between migraine and multiple sclerosis (MS) was recognized more than half a century ago when Compston and McAlpine \[[@CR1]\] reported that 2% of MS patients developed migraines within 3 months of their first relapse. The association between migraine and MS was observed in two case--control series \[[@CR2], [@CR3]\] that predated introduction of the International Classification of Headache Disorders (ICHD-2) \[[@CR4]\]. Four of five subsequent controlled studies \[[@CR2], [@CR3], [@CR5]--[@CR7]\] and several uncontrolled studies that used ICHD-2 criteria confirmed that headache prevalence is elevated among persons with MS \[[@CR8]--[@CR11]\]. Among these is a population-based study from Sicily that reported a doubling of headache prevalence in MS patients compared to controls \[[@CR5]\]. Only one study did not detect a statistically significant difference in headaches between MS patients and historical controls \[[@CR7]\], possibly due to very high prevalence of primary headaches in the local population.

It is not clear if the association between headache and MS is specific to migraine. Pöllmann et al. \[[@CR10], [@CR11]\] observed that among interferon-treated MS patients, migraine was predominant headache type while tension-type headache predominated among those not treated with interferon.

The question of whether co-existing migraine in an MS patient affects the symptomatology, comorbidity, and course of MS has not been well explored. An observed association between presence of migraine and relapsing--remitting course of MS \[[@CR3], [@CR9]\], has not been reported in all studies. As some comorbidities have recently been shown to be risk factors for increased MS severity \[[@CR12]\] this issue acquires special relevance.

The objectives of our study were threefold: (1) to compare the relative frequency of migraine in an MS specialty clinic and in population controls using the validated self-administered diagnostic questionnaire from the American Migraine Prevalence and Prevention (AMPP) study \[[@CR13]\]; (2) to compare the 'MS--migraine group' with the 'MS--no headache' group with respect to symptom profile and co-existing diagnoses, with special attention to psychiatric disorders, which are known to be more frequent among migraineurs \[[@CR14]--[@CR16]\]; (3) to compare radiographic (MRI) markers of disease in MS migraineurs and in headache-free MS.

Methods {#Sec2}
=======

NYU-MS Care Center serves an ethnically and socio-economically diverse population of over 2,400 MS patients in the greater New York area. Eligible patients were over 18 years of age, had diagnosis of MS by the revised McDonald criteria and fluent understanding of written English. They completed a questionnaire at the time of routinely scheduled clinic visits over a 3-month period from October 2006 to January 2007. The study was approved by Institutional Review Board of New York University Medical Center.

We aimed to collect over 200 responses as this would allow us to separate observed prevalence of migraines from the historical controls (13%) \[[@CR17]\], if the observed prevalence is less than 9.4% or more than 19.5%, with confidence intervals on prevalence estimates of \>95%.

Questions on headache frequency and characteristics were identical to those in the validated diagnostic questionnaire included in the American Migraine Prevalence and Prevention (AMPP) study, the largest epidemiological study of migraine to date. This questionnaire assesses the characteristics of up to three patient-identified headaches and has a sensitivity of 100% and specificity of 82% for an ICHD-2-based gold standard diagnosis of migraine \[[@CR17]\]. Diagnoses were assigned using identical data and procedures in the NYU-MS Care Center and in the AMPP study \[[@CR13]\]. Prevalence of various headaches in MS patients from the NYU-MS Care Center was compared to that in AMPP cohort. Migraine severity was assessed using the validated Migraine Disability Assessment (MIDAS) tool \[[@CR18]\]. Comorbidities were assessed in the MS patients using the same instruments as in the AMPP-Patient Health Questionnaire (PHQ-9) for depression, Patient Health Questionnaire (PHQ) for anxiety and Allodynia Symptom Check list for allodynia. Additional questions, not included in the AMPP, addressed MS duration and treatment, fatigue (Fatigue Severity Scale), daytime sleepiness (Epworth Sleepiness Scale), and brainstem and visual symptoms using questions developed specifically for this study. We also assessed rates of 'episodic neurologic dysfunction' (END) defined as 'a new neurological symptom, or significant worsening of preexisting symptom(s) of more than 24 h in duration'. Although END definition mirrors that of MS relapse in the McDonald's criteria, we use the former term because our patients were not necessarily examined at the time of their new or worsening symptoms and so we were unable to corroborate patients' report of worsening with objective findings on examination and exclude possibility of intercurrent infection/stressor. Thus, ENDs could represent bona fide relapses or 'pseudo-exacerbations' (unmasking of previous deficits due to physiological or psychological stressors). The definition of END was provided in the questionnaire, along with a list of typical neurologic symptoms reported during an MS relapse. Patients were asked to estimate the number of ENDs they had experienced over the previous year. Patients' disability level was assessed with Patient-Derived Disability Steps. PDDS is a surrogate measure of the Expanded Disability Status Scale (EDSS) and correlates well with the EDSS in both cross-sectional and longitudinal assessments \[[@CR19]\].

Brain MRIs completed on participating patients within 2 years of the survey were reviewed by an MS neurologist and an expert in MS neuroradiology blind to the patients' clinical history. MRI scans included T2-weighted, and pre- and post-contrast T1-weighted sequences. All scans were done at 1.5-T magnet machine with exception of five scans that were done at 3-T magnet and two scans at 0.6-T magnet. The number of hyperintense lesions on brain T2-weighted scans, hypointense lesions on T1-weighted scans and gadolinium-enhancing lesions on post-contrast T1-weighted sequence were recorded, as were the number of T2 hyperintense lesions in periventricular white matter, subcortical white matter, corpus callosum, brainstem and basal ganglia. Lesions involving a given structure were considered as separate, and therefore counted individually, if regions of normal signal intensity were present between slices.

Group comparisons were carried out using *t* tests for continuous variables and Chi-squared test for differences in proportions. A series of logistic regression models were used to assess the association of migraine on a variety of outcome measures in persons with MS. The main predictor variable was migraine status. We controlled for age, gender, disease duration, β-interferon use and depression (coded as 'yes'/'no' variable, with 'yes' defined as score of 10 or more on PHQ-9, which corresponds to moderate depression cut-off). Separately modeled dichotomous outcome variables included common MS and pain symptoms: optic neuritis, trigeminal neuralgia, facial pain, occipital neuralgia, Lhermitte's sign, cognitive, visual and brainstem symptoms, restless legs syndrome, painful spasms, body pain, allodynia, temporomandibular joint syndrome and analgesic use.

We also used linear regression to assess the impact of age, gender, disease duration, beta-interferon use and depression on continuously distributed outcome variables. To assess the influence of migraine disability on symptom profiles, we conducted analyses stratified by MIDAS grade using the four-level disability scoring grading \[Grade I, none--mild (0--5); Grade II, moderate (6--10); Grade III, severe (11--20); Grade IV (\>20)\] \[[@CR20]\]. Statistical analyses were carried out using SPSS Statistics v. 17.0 software.

Results {#Sec3}
=======

Frequency and characteristics of migraines in MS patients and AMPP historical controls {#Sec4}
--------------------------------------------------------------------------------------

The questionnaire was distributed to 225 patients in the waiting room of NYU-MS Center, and 204 (90%) returned a completed questionnaire; 64% of patients (131) reported "a headache within the past year not related to trauma, infection or medication". Of the 131 patients with a headache, 94 (72%) met ICHD-2 criteria for migraines and the remaining 37 (28%) for tension-type headaches. There were ten migraineurs (9.4%) who had a second headache type that met criteria for tension-type headache. The patients with migraine and non-migraine headache were included in the migraine group. In this report, we compare MS migraineurs (MS-Mig)---this group consisted of 94 patients---with headache-free MS (MS-NH) patients, 73 patients. In general, patients with tension-type headache and MS had clinical characteristics intermediate between those of the non-headache controls and the migraine cases. Data on tension-type headache group will be presented in a separate publication.

AMPP population consisted of 162,576 responders, of whom 18,968 individuals met ICHD-2 criteria for migraine yielding an unadjusted 1-year period prevalence estimate of 11.7% (5.6% for men and 17.1% for women) \[[@CR13]\]. Relative frequency of migraine in MS outpatients was more than threefold higher than in the AMPP population controls both for men (18.4 vs. 5.6%, RR = 3.29, *p* \< 0.001) and for women (55.7 vs. 17.1, RR = 3.36, *p* \< 0.001). Migraine frequency among women with MS was significantly higher for each age groups (20--29, 30--39, 40--49 and 50 and above) compared to AMPP controls. There were too few men with both MS and migraine to allow for age-adjusted analysis.

Thirty-six percent of MS-Mig group had auras. Among those with aura, most were visual (44.1% of auras), or visual/sensory (38.2%), and a minority, sensory only (17.6%). The frequency of migraine with aura and distribution of aura types is nearly identical to that of migraineurs in the AMPP cohort \[[@CR20]\]. Migraine disability, as assessed with MIDAS, did not differ in the MS and in the AMPP samples: 77% of MS-Mig and 75% of the AMPP migraineurs had mild-to-moderate migraine-related disability (MIDAS Grades 1 and 2), while the remainder fell into migraine Grades 3 and 4. Six patients in the MS cohort (6.4%) had chronic migraines; all six met criteria for medication overuse headache.

Demographic characteristics, past medical and family history {#Sec5}
------------------------------------------------------------

The demographic characteristics, frequencies of co-existing conditions and family history of MS and migraines in MS-Mig and MS-NH are presented in Table [1](#Tab1){ref-type="table"}. The two groups were similar with respect to age (47 ± 13 vs. 43 ± 11 years), and disease duration (13 ± 11 vs. 12 ± 11 years), but MS-Mig had a larger fraction of women compared to MS-NH (90 vs. 57%, *p* \< 0.001).Table 1Demographic characteristics, co-existing medical conditions and family history in MS-Mig and MS-NH groupsMS-NHMS-Mig*pN*7394--Age in years (mean ± SD)47 ± 1343 ± 11NS% Female\*57%90%\<0.001Disease duration in years (mean ± SD)13 ± 1112 ± 11NS% Interferon beta-1 use71%64%NSCo-existing conditions Hypertension12%15%NS Diabetes0%4%NS Seizures1%4%NS Syncope1%7%NS Thyroid disease8%10%NS Fibromyalgia0%4%NS Mononucleosis\*5%20%0.006 Autoimmune disease4%12%NS Bipolar disorder4%3%NS Anxiety spectrum disorder8%16%NS Depression21%36%0.028 Current smoker18%19%NSFamily history Family history of MS17%10%NS Family history of migraine\*19%49%\<0.001*MS-Mig* MS and migraine group, *MS-NH* MS--no headache group, *NS* non-significant\* *p* \< 0.01

MS-Mig were more likely than MS-NH to report history of depression (36 vs. 21%, *p* \< 0.028), and scored higher on PHQ-9 scales for depression (8.2 vs. 4.7, *p* \< 0.001). More MS migraineurs reported a history of mononucleosis compared to headache-free MS patients (20 vs. 5%, *p* \< 0.01), while the rates of other co-existing conditions were similar.

Family history of MS in first-degree relatives was not different in the two groups, but family history of migraines was 2.5 times higher (49%) among MS-Mig than in MS-NH (19%), and 3.5 times higher in the MS-Mig with aura subset (59%) compared to MS-NH.

Episodic neurologic dysfunction in MS migraineurs and headache-free MS patients {#Sec6}
-------------------------------------------------------------------------------

Episodic neurologic dysfunction (END) that lasted more than 24 h was reported more frequently by MS-Mig group compared to MS-NH group. In the MS-Mig group, 28% had three or more ENDs over past year, and only 20% had none. By contrast, only 10% of MS-NH reported three or more ENDs and 32% had none. The fraction of patients with either one or two ENDs was similar in the two groups. Patients who had never experienced an END likely had primary progressive form of MS; these patients constituted a relatively larger proportion of the MS-NH (9%) than of the MS-Mig (3%) group. The trend towards the increased number of ENDs was most pronounced in the subset of patient with migraine with aura (*N* = 29). In the MS-Mig with aura subset, 52% reported three or more ENDs over past year and only 7%, no ENDs.

Pain-related and non-pain-related symptom profiles {#Sec7}
--------------------------------------------------

The prevalence of specific pain-related symptoms, such as Lhermitte's sign, occipital and trigeminal neuralgia, facial pain, temporomandibular joint pain, spasms, and restless legs syndrome, was 2--5 times higher in MS-Mig than in MS-NH (Table [2](#Tab2){ref-type="table"}). Frequent, non-headache-related allodynia was reported by 26% of migraineurs and only 4% of headache-free patients. Over 20% of the MS-Mig group required analgesics for non-headache reasons on a daily basis, compared to 6% in MS-NH group (Table [2](#Tab2){ref-type="table"}). Over-the-counter medication, NSAIDS and acetaminophen, were used for headache by 80 of the 94 migraineurs (85%).Table 2Painful symptoms and analgesic use in MS-Mig and MS-NH groupsMS-NH (%)MS-Mig (%)*p*ORCIBrief, shooting pains into jaw\*527\<0.0019.72.1--44Shooting pains into back of head/neck\*1145\<0.0019.22.7--32Facial pain\*10320.0016.61.6--27Temporomandibular joint syndrome\*730\<0.0014.81.4--16Lhermitte's sign\*1848\<0.0015.21.9--14Painful spasms\*29480.0123.71.4--9.6Restless legs feeling, movement-relieved\*33570.0022.10.87--4.8Frequent allodynia (not during headache)\*426\<0.0015.31.2--23Daily use of pain medication for non-headache\*6210.0067.31.2--46\* *p* \< 0.01

MS-Mig had considerably more cognitive, psychiatric, brainstem and visual symptoms, and scored higher on depression and anxiety scales (PHQ-9, PHQ), fatigue severity scale and Epworth sleepiness scale than MS-NH patients (Table [3](#Tab3){ref-type="table"}).Table 3Non-pain symptoms in MS-Mig and MS-NH groupsMS-NHMS-Mig*p*ORCIOptic neuritis\*49%77%\<0.0012.81.2--6.4Visual problems interfere with reading22%32%NS0.640.25--1.7Brainstem symptoms\*,^a^27%53%0.0012.41.0--5.7Cognition "definitely affected"24%38%0.0391.80.67--4.9Depression score (PHQ-9)4.78.2\<0.001NANAAnxiety score (PHQ)4.16.5\<0.001NANAFatigue severity score3.65.0\<0.001NANAHours of sleep per night6.76.8NSNANAEpworth sleep scale score\*5.68.1\<0.001NANA\* *p* \< 0.01^a^Double vision, facial weakness, deafness, abnormal taste, vertigo

To control for potential confounders, we modeled the relationship between migraine status and MS related outcomes using logistic regression to account for age, gender, disease duration, β-interferon use and depression (defined as score of 10 or more on PHQ-9). MS related outcomes associated with migraine at the *p* \< 0.01 level include trigeminal neuralgia, occipital neuralgia, facial pain, painful spasms, Lhermitte's sign, temporomandibular joint pain and non-headache pain. Migraine was not a predictor of cognitive, brainstem or visual symptoms, restless legs syndrome, allodynia or daily pain medication use. Depression was a significant predictor of visual and cognitive problems. Gender was a predictor of painful spasms and disease duration was a predictor of Lhermitte's sign and brainstem symptoms. The results of logistic regression analyses are presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} as odds ratios with 95% confidence.Table 4Predictors of non-pain MS symptoms, according to a multivariate logistic regression model using a forward selection criteriaOptic neuritisVisual problemsCognitive symptomsNo migraine versus migraine0.300 (0.145--0.621)No depression versus depression0.232 (0.103--0.522)0.197 (0.084--0.458)No IFNβ use versus IFNβ use3.178 (1.427--7.078)Values are OR and 95% CI after forward selection criterion, *p* \< 0.01Age, gender, disease duration, IFNβ usage, migraine and depression where not significant predictors of brainstem symptoms; age, gender and disease duration were not significant predictors of any MS symptoms; *p* ≤ 0.01Table 5Predictors of pain symptoms, according to a multivariate logistic regression model using a forward selection criteriaTrigeminal neuralgiaFacial painOccipital neuralgiaTMJLhermitte's signRLSNon-facial painsAllodyniaDaily pain medicationNo migraine versus migraine0.145 (0.041--0.511)0.197 (0.064--0.608)0.103 (0.034--0.313)0.237 (0.084--0.667)0.211 (0.092--0.486)0.165 (0.074--0.364)No depression versus depression0.296 (0.131--0.666)0.242 (0.095--0.615)0.192 (0.066--0.522)Values are OR and 95% CI after forward selection criterion. *p* ≤ 0.01Age, gender, disease duration, IFNβ usage, migraine and depression were not significant predictors of painful spasms; age, gender, disease duration and IFNβ usage were not significant predictors of any symptom

We modeled the relationship of migraine status to a series of continuous outcomes using linear regression. These models were adjusted for the same independent variables used in the logistic models (migraine status, age, gender, disease duration, β-interferon use and depression). Migraine was a significant predictor of anxiety and nearly reached significance for Epworth sleepiness scale (*p* = 0.013), while depression and disease duration were significant predictors of fatigue. Age and gender were not predictive of any outcome variable.

Importantly, despite the more symptomatic course, the disability of MS migraineurs, as assessed by Patient-Derived Disability Score (PDDS) was mild---nearly all could ambulate without assistive device---and was similar to those without headache.

Side-effects of interferon-beta 1 {#Sec8}
---------------------------------

Interferon-beta (IFNβ-1) use was similar in the two groups (71% for MS-NH and 64% for MS-Mig, *p* \> 0.1), and the remainder were using glatiramer acetate or were on no medication. MS-Mig reported more side-effects to interferons than MS-NH: 32% of MS-Mig patients had flu-like symptoms following 'all or almost all injections' compared to only 13% headache-free patients. Furthermore, 34% of migraineurs on IFNβ-1a had a headache within 24 h of the injection "always or almost always", while the no-headache group did not have post-injection headache.

Radiological characteristics of MS-Mig and MS-NH groups {#Sec9}
-------------------------------------------------------

Brain MRIs performed within 2 years of the survey were available for 138 out of 204 patients in the study (67%), including 65 MRIs of MS-Mig and 49 of MS-NH patients. The remaining MRIs were of patients with tension-type headache, and will be discussed in a separate publication. Table [6](#Tab6){ref-type="table"} compares the radiographic findings of the two groups. There were no differences in the number or distribution of T2 hyperintense lesions or the number of gadolinium-enhancing lesions in the MS-Mig and MS-NH groups. There was a trend for more T1 hypointense lesions in the headache-free group (*p* \< 0.05).Table 6Brain MRI characteristics of MS-Mig and MS-NH groupsMS-NHMS-Mig*p*No. of brain MRI4965\# of T2 hyperintense lesions21.519.6NS\# of T2 hyperintense lesions \<5 mm7.08.2NST2 hyperintense lesions by location Periventricular7.35.8 Subcortical9.911.3 Basal ganglia1.10.3 Corpus callosum2.01.3 Brainstem0.60.4\# of T1 gadolinium-enhancing lesions0.30.5NS\# of T1 hypointense lesions6.03.3\<0.05

Discussion {#Sec10}
==========

The overall prevalence of headache in our MS sample was 64%, which is within the range reported in several previous studies \[[@CR8]--[@CR11]\]. Majority of headache seen in MS patients, 72%, were migraines. In comparison with AMPP historical controls, migraine was threefold more common in MS outpatients. The increased relative frequency of migraine is consistent with most controlled studies of headache in MS \[[@CR2], [@CR3], [@CR6]\].

Several possible reasons for the association can be suggested. One possibility is that headaches are directly attributable to MS ('secondary headaches'). One consideration that mitigates against this possibility is that MS-Mig group had an elevated family history of migraine in comparison to those without migraine. If the excess of migraine-like headaches were attributable to MS, this result would not be expected. Furthermore, migraine characteristics in the MS patient and general population such as the distribution of migraine-related disability grades (MIDAS grade), and the ratio of migraine with aura to migraine without aura were nearly identical in the MS clinic and the general population \[[@CR13], [@CR20]\]. If 'MS migraine' were a distinct entity, it would be more probable that its characteristics would be distinguishable from those of primary migraines. Accurate data on temporal relationship between MS and migraine could help clarify the nature of association. To this end, longitudinal studies in which mechanistic hypotheses will be developed and explored should be pursued.

Our study is the first to investigate both clinical and radiographic profiles of MS in patients with and without migraine. The MS-Mig group had a remarkable increase in the frequency of both pain-related and non-pain-related symptoms. MS-Mig group also reported significantly more episodes of neurologic dysfunction and were likely to have progressive form of MS, confirming a previously observed association between migraines and the relapsing form of MS \[[@CR9]\].

We carried out separate analyses comparing headache-free patients to the subset of MS-Mig with very mild migraines (MIDAS Grade 1) and more severe migraines (Grades 2--4). We observed significant increases in ENDs rates and symptom frequencies in both mild migraine and severe migraine subgroup compared to non-headache group (data not shown). This threshold effect suggests that the presence of migraine, rather than attack frequency and severity, accounts for the increased symptom frequency in MS-Mig subset.

Why do MS migraineurs appear to be so much more prone to experience new or worsening neurological symptoms than MS patients who do not have migraines? It seems unlikely that ENDs represent a direct expression of migraine aura since most auras subside within an hour and we specifically enquired about symptoms whose duration exceeds 24 h. Furthermore, increases in symptom frequency were observed both in MS migraineurs with auras and those without. Two potential explanations for increased symptom rate in MS migraineurs may be considered: (1) migraine may trigger more severe inflammation in the brain, in which case, increased number of T2 hyperintense lesions, and, especially, of T1 gadolinium-enhancing lesions, would be expected on brain MRIs of MS-Mig compared to MS-NH patients; or, (2) migraineurs may report more symptoms of MS at an equivalent level of brain pathology, inasmuch as they experience altered pain perception and have a decreased pain threshold, a phenomenon thought to be due to central sensitization \[[@CR21]--[@CR25]\]. In the latter case, lesion burden on MRI would not be expected to differ in the two groups.

In our study, T2 and gadolinium-enhancing lesion burden was the same in the two groups, in agreement with a previous report, in which total number of T2 lesions in MS migraineurs did not differ from MS non-migraineurs \[[@CR26]\]. Since elevated symptom and END rates in MS-Mig did not translate into greater lesion burden on their MRI, it appears more plausible that the more elaborate symptomatology in the migraineurs is not due to more active MS disease activity in that patient subset, but to their greater susceptibility to manifesting neurologic symptoms. This explanation of increased symptom rates in migraineurs may also account for our finding that patient's disability did not differ between the two groups.

Another hypothesis that is relevant to a subset of migraineurs with aura is that cortical spreading depression of migraine aura causes unmasking of MS symptoms. If this were the case, then we would find that migraineurs with aura (MA) experience even more ENDs than migraineurs without aura. Indeed, 52% of MA patients reported three or more ENDs over the past year, compared to 38% in the all-migraineur group, and 10% in the no-headache group. By contrast, only 7% of MA patients had no ENDs over the past year, as compared to 20% of the all-migraineur group and 32% in the no-headache group (data not shown). Thus, it is possible that migraine aura may trigger prolonged neurological deficits with recovery analogous to the unmasking of deficits in experimental lesions by cortical spreading depression \[[@CR27]\]. One practical ramification of this observation is that an MS patient who has migraine with aura may need to be aggressively treated for migraine in order to prevent not only his migraines, but also prolonged episodes of neurological disability that may be triggered by migraine aura.

We conclude that the greater susceptibility of migraineurs to experience symptoms relating to apperception may be due to decreased pain and visual discomfort thresholds in these patients and their proclivity to allodynia \[[@CR24], [@CR28]\] or to induction of 'pseudoexacerbation' via cortical spreading depression. Whether the discrepancy in symptom frequency between and MS migraineurs and non-migraineurs extends to the non-sensory realms as well (e.g. motor, or autonomic function deficits, or extraocular movement abnormalities) is an important question that cannot be answered with our data.

Migraine is comorbid with depression in the general population \[[@CR14]--[@CR16]\] and our study extends this association to MS population. MS migraineurs reported history of depression at significantly higher rates than headache-free MS patients, and also scored higher on PHQ-9 scale for depression. It is important to note that higher END rates and symptom frequencies in the MS-Mig group cannot be attributed to higher rates of depression in that group as migraine was a significant predictor of most pain-related symptoms even in the logistic regression model that included depression as one of the dependent variables.

Consistent with most previous reports \[[@CR6], [@CR11], [@CR30]\], MS migraineurs tended to be intolerant of IFNβ-1: one in three experienced a headache 'always or almost always' following the injection. Even those with no change in migraine pattern experienced flu-like symptoms at a significantly higher rate than headache-free patients. In clinical practice, it would seem prudent to question all MS migraineurs who are initiated on β-interferon therapy for any change in headache pattern and for flu-like symptoms since these side-effects may have a considerable detrimental impact on their quality of life and adherence to therapy.

One drawback of our study is that it was conducted in a waiting room of a specialty MS clinic. Although, NYU-MS Center serves patients from all socio-economic strata, and the demographics of our patient population are reflective of MS patients in our area (National MS Society survey, 2007, data on file), clinic patients may be skewed toward the more severe end of the disability spectrum. Moreover, studies carried out within medical institutions tend to overestimate rates of association with comorbid disorders, a phenomenon known as 'Berkson's bias' \[[@CR29]\].

Another potential objection to the study is that the elevated frequency of migraines seen in our patient population is due, at least in part, to the wide-spread IFNb-1 use at our Center, which could trigger and exacerbate migraines \[[@CR6], [@CR11], [@CR30]\]. To address this objection, we conducted logistic regression modeling that was adjusted for interferon use. Migraine remained a significant predictor of most MS symptoms in this analysis as well (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}).

Conclusions {#Sec11}
===========

Our study demonstrates that relative frequency of migraine is increased threefold in MS patients attending a specialty clinic compared to historical population controls. Migraine disability was considerable among MS patients: nearly one in four was classified in moderate or severe MIDAS grades. Migraines in MS are very common, often disabling, yet potentially treatable. Headache history should therefore be elicited from all MS patients.

A novel result of our study is a description of 'MS migraineur' who may be distinguished from a headache-free counterpart by a higher probability of episodic neurologic dysfunction, pain-related symptoms, and higher rates of depression and anxiety. Population-based, prospective studies with objective documentation of relapses, cognitive and physical disability, regular MRI brain examination and controlled for IFNb-1 use, psychiatric comorbidities, presence of alexithymic trait, are necessary to clarify the nature of the association between migraine and MS, and to confirm our finding that MS migraineurs experience a markedly more symptomatic, but not necessarily more disabling, MS course.
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